All In Biotech

NDA 021977 · Takeda Pharms USA

Vyvanse

Lisdexamfetamine Dimesylate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Feb 23, 2007

Approved uses

10

Original approval plus efficacy supplements

Registered trials

117

33 Phase 3, 5 recruiting

FAERS reports

33,465

13,613 serious, 307 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing VYVANSE, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout VYVANSE treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) , Drug Abuse and Dependence (9.2) ] . WARNING: ABUSE, MISUSE, AND ADDICTION See...

What it is approved for

From the label in effect Apr 30, 2026.

VYVANSE ® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1) ]. Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2) ] . VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of ( 1 ): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults Limitations of Use : The use of VYVANSE is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ) VYVANSE is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established ( 5.2 ) Limitations of Use: The use of VYVANSE is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ] . VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established [see Warnings and Precautions (5.2) ] .

Mechanism: Lisdexamfetamine is a prodrug of dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 60MG · CAPSULE, ORAL · Prescription · TE AB
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 20MG · CAPSULE, ORAL · Prescription · TE AB
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 50MG · CAPSULE, ORAL · Prescription · TE AB
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 10MG · CAPSULE, ORAL · Prescription · TE AB
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 40MG · CAPSULE, ORAL · Prescription · TE AB
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 70MG · CAPSULE, ORAL · Prescription · TE AB
  • VYVANSE · LISDEXAMFETAMINE DIMESYLATE 30MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lisdexamfetamine Dimesylate" as an intervention, any sponsor and status, largest first.

All 117 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,768
  • fatigue2,100
  • off label use2,063
  • anxiety1,851
  • headache1,805
  • nausea1,597
  • product availability issue1,583
  • insomnia1,505
  • depression1,415
  • feeling abnormal1,368
  • product use issue1,335
  • disturbance in attention1,284

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2007300
2008974
20091,147
2010431
2011377
2012415
2013502
20141,419
20152,219
20163,132
20171,872
20181,904
20191,777
20201,804
20211,700
20222,503
20233,169
20243,256
20252,700
20261,864

Recalls

1 FDA enforcement reports for this application.

  • Sep 2, 2016 · Class III · Terminated

    Presence of Foreign Tablets/Capsules

Shortages

FDA's drug shortage list.

  • Current · updated Nov 2, 2026

    Vyvanse, Capsule, 60 mg (NDC 59417-106-10).

  • Current · updated Nov 2, 2026

    Vyvanse, Capsule, 70 mg (NDC 59417-107-10).

  • Current · updated Nov 2, 2026

    Vyvanse, Capsule, 10 mg (NDC 59417-101-10).

  • Current · updated Nov 2, 2026

    Vyvanse, Capsule, 40 mg (NDC 59417-104-10).

  • Current · updated Nov 2, 2026

    Vyvanse, Capsule, 50 mg (NDC 59417-105-10).

  • Current · updated Nov 2, 2026

    Vyvanse, Capsule, 20 mg (NDC 59417-102-10).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vyvanse (Lisdexamfetamine Dimesylate)

2024 spending

$88.8M

Beneficiaries

41,415

212,410 claims

Per beneficiary

$2,145

$12.88 per unit

View as table
YearSpending
2020$95,861,742
2021$108,096,030
2022$127,207,219
2023$138,990,768
2024$88,828,576

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 126 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.